Risk Disclosure In Rx Ad “Brief Summary” To Be Examined By Modified FDA Study
Executive Summary
FDA is modifying its upcoming studies of brief summaries in Rx advertising to assess whether changes such as organizing side effects into short- and long-term categories would aid comprehension
You may also be interested in...
FDA Advertising Oversight Will Consider Impact Of “Puppies” And The Internet
FDA is pushing forward several research initiatives to help better define how print and broadcast direct-to-consumer ads should be structured, but the agency is adopting a less formal approach to oversight of Internet advertising
FDA Advertising Oversight Will Consider Impact Of “Puppies” And The Internet
FDA is pushing forward several research initiatives to help better define how print and broadcast direct-to-consumer ads should be structured, but the agency is adopting a less formal approach to oversight of Internet advertising
DTC Risk Disclosures Examined By FDA; Do Minor Risks Swamp Major Ones?
FDA will evaluate how the presence of minor safety risks in the brief summary of print direct-to-consumer advertisements impacts consumer comprehension of major risks